Celsion (CLSN) Misses Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Celsion (CLSN) Misses Q1 EPS by 2c

Celsion Corporation Reports First Quarter 2015 Financial Results and Provides Business Update

May 12, 2015 8:00 AM EDT

LAWRENCEVILLE, N.J., May 12, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2015 and provided an update on its development programs, including ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, and GEN-1, an IL-12 DNA-based immunotherapy encased in a synthetic nanoparticle delivery system, which is currently under development for the localized treatment of ovarian and brain cancers. 

"Over the past quarter, we have reported meaningful progress with both ThermoDox® and GEN-1," said Michael H. Tardugno, Celsion's chairman, president and CEO. ... More